This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.
Using and Sequencing EGFR Exon 20-Targeted Therapies for NSCLCApril 27th 2022
Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Identifying Second-Line Options for NSCLC With EGFR Exon 20 InsertionsJuly 8th 2022
During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLCAugust 3rd 2022
During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.